Eckert & Ziegler SE's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 60.42.
Eckert & Ziegler SE's Days Inventory for the
three
months ended in Mar. 2026 was 115.81.
Eckert & Ziegler SE's Days Payable for the
three
months ended in Mar. 2026 was 23.15.
Therefore, Eckert & Ziegler SE's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 153.08.
Eckert & Ziegler SE (XTER:EUZ) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Eckert & Ziegler SE Cash Conversion Cycle Related Terms
Eckert & Ziegler SE Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Eckert & Ziegler SE's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:EUZ vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's Cash Conversion Cycle falls into.
Eckert & Ziegler SE Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Eckert & Ziegler SE's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eckert & Ziegler SE (XTER:EUZ) has a Cash Conversion Cycle of 153.08 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Eckert & Ziegler SE and its competitors.
Is Eckert & Ziegler SE's Cash Conversion Cycle too high?
Eckert & Ziegler SE's current Cash Conversion Cycle is 153.08. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Eckert & Ziegler SE's value of 153.08 is 2.5% below this industry median. Overall, Eckert & Ziegler SE has a GF Score™ of 99/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's Cash Conversion Cycle compare to ABT and SYK?
Eckert & Ziegler SE's Cash Conversion Cycle of 153.08 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Eckert & Ziegler SE's value of 153.08 is 2.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current Cash Conversion Cycle of 153.08 is 2.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current Cash Conversion Cycle is 153.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (XTER:EUZ) is currently considered Fairly Valued. The stock's GF Value™ is €16.26, compared to a current price of €15.90 — trading 2.2% below its estimated fair value. The current Cash Conversion Cycle is 153.08 and 2.5% below the Medical Devices & Instruments industry median of 156.96. Eckert & Ziegler SE's overall GF Score™ is 99/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Eckert & Ziegler SE (XTER:EUZ), the current Cash Conversion Cycle is 153.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (XTER:EUZ) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.90 is trading 2.2% below its estimated GF Value™ of €16.26.
GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.
Key valuation signals for XTER:EUZ:
Cash Conversion Cycle: 153.08
GF Value™: €16.26 vs. price of €15.90 (2.2% below fair value)
Industry Position: 2.5% below the Medical Devices & Instruments median
No single metric tells the full story. See the XTER:EUZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
99GF Score
Get the complete analysis for XTER:EUZ
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:EUZ has been successfully added to your 
